Innovative Diagnostic Platform Epic Sciences specializes in developing non-invasive liquid biopsy diagnostics that enable real-time monitoring of cancer progression and treatment response, offering significant value to pharma companies and healthcare providers seeking advanced diagnostic tools.

Recent Funding Growth With a recent Series G investment of $24 million led by prominent investors like Deerfield Management and Arsenal Capital Partners, the company has strengthened its financial position to expand its market reach and accelerate product commercialization.

Strategic Collaborations Epic Sciences partners with leading pharmaceutical companies and major cancer centers worldwide, creating opportunities for sales of its diagnostics to various stakeholders involved in personalized cancer treatment and clinical trials.

New Product Launches The launch of innovative blood tests such as DefineMBC indicates a growing portfolio of diagnostic solutions, presenting sales opportunities across the oncology diagnostic market and laboratories focused on metastatic breast cancer.

Market Positioning Operating in the lucrative liquid biopsy and oncology diagnostics space with aspirations to improve treatment outcomes, Epic Sciences is well-positioned to capture the ongoing trend towards precision medicine within the rapidly expanding cancer care sector.